Sign In
Buy HRMY
$35.24
-0.620 (-1.73%)
At Close: Jul 31, 2026
Did Harmony Biosciences Holdings, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate- HRMY
07:30am, Tuesday, 05'th Nov 2024
NEW YORK, NY / ACCESSWIRE / November 5, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Harmony Biosciences Holdings, Inc. ("Harmony Biosciences Holdings, Inc.") (
NEW YORK, NY / ACCESSWIRE / November 4, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Harmony Biosciences Holdings, Inc. ("Harmony Biosciences Holdings, Inc.") (
Are Investors Undervaluing Harmony Biosciences (HRMY) Right Now?
10:46am, Friday, 01'st Nov 2024
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
NEW YORK, NY / ACCESSWIRE / November 1, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Harmony Biosciences Holdings, Inc. ("Harmony Biosciences Holdings, Inc.") (
HRMY vs. REGN: Which Stock Is the Better Value Option?
12:41pm, Thursday, 31'st Oct 2024
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Harmony Biosciences Holdings, Inc. (HRMY) and Regeneron (REGN). But which of these two s
NEW YORK, NY / ACCESSWIRE / October 31, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Harmony Biosciences Holdings, Inc. ("Harmony Biosciences Holdings, Inc.") (
Harmony Biosciences Holdings, Inc. Announces Pricing of Public Offering of Common Stock by Selling Shareholders
10:30pm, Wednesday, 30'th Oct 2024
PLYMOUTH MEETING, Pa. , Oct. 30, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) (the "Company") today announced the pricing of the previously announced underwritten public offe
HRMY ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of Harmony Biosciences Holdings, Inc. Shareholders Who Lost Money
06:10am, Wednesday, 30'th Oct 2024
NEW YORK, NY / ACCESSWIRE / October 30, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Harmony Biosciences Holdings, Inc. ("Harmony Biosciences Holdings, Inc.") (
Harmony Biosciences Holdings, Inc. Announces Commencement of Proposed Public Offering of Common Stock by Selling Shareholders
05:15pm, Tuesday, 29'th Oct 2024
PLYMOUTH MEETING, Pa. , Oct. 29, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) (the "Company") today announced the commencement of an underwritten public offering of up to 8,0
Harmony Biosciences Holdings, Inc. (HRMY) Q3 2024 Earnings Call Transcript
01:43pm, Tuesday, 29'th Oct 2024
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY ) Q3 2024 Earnings Conference Call October 29, 2024 8:30 AM ET Company Participants Brennan Doyle - Head of Investor Relations Jeffrey Dayno - President
Harmony Biosciences Holdings, Inc. (HRMY) Q3 Earnings and Revenues Surpass Estimates
09:41am, Tuesday, 29'th Oct 2024
Harmony Biosciences Holdings, Inc. (HRMY) came out with quarterly earnings of $0.79 per share, beating the Zacks Consensus Estimate of $0.64 per share. This compares to earnings of $0.63 per share a y
Harmony Bio, The No. 1 Biotech Stock, Surged On Its 'High-Quality' Beat
09:27am, Tuesday, 29'th Oct 2024
Harmony Biosciences stock jumped Tuesday on the biotech company's "high-quality" third-quarter beat on the back of its narcolepsy drug.
NEW YORK, NY / ACCESSWIRE / October 29, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Harmony Biosciences Holdings, Inc. ("Harmony Biosciences Holdings, Inc.") (
NEW YORK, NY / ACCESSWIRE / October 23, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Harmony Biosciences Holdings, Inc. ("Harmony Biosciences Holdings, Inc.") (
Harmony Biosciences Holdings, Inc. (HRMY) Earnings Expected to Grow: Should You Buy?
11:05am, Tuesday, 22'nd Oct 2024
Harmony Biosciences (HRMY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
